Figure 4.
EYA2 expression and impact on survival and hematopoiesis. (A) Relative gene expression of EYA2 using the NTUH data set showing significantly higher EYA2 expression in MDS case subjects compared with control subjects. (B) EYA2 gene expression is higher in lower risk disease subtypes, including RARS and RCMD. (C) Kaplan-Meier plot showing that higher EYA2 expression is associated with improved OS. (D) Western blot showing activation of innate immune signaling after EYA2 transfection. (E) Representative micrographs (40×) of colony-forming capacity assays of control (i) or EYA2 inhibitor–treated (ii, 1 µM; iii, 10 µM) MDS bone marrow mononuclear cells showing significantly greater erythroid colonies in treated samples with accompanying quantitation for each of 3 independent samples (mean ± standard error). *P < .005, **P < .0001.

EYA2 expression and impact on survival and hematopoiesis. (A) Relative gene expression of EYA2 using the NTUH data set showing significantly higher EYA2 expression in MDS case subjects compared with control subjects. (B) EYA2 gene expression is higher in lower risk disease subtypes, including RARS and RCMD. (C) Kaplan-Meier plot showing that higher EYA2 expression is associated with improved OS. (D) Western blot showing activation of innate immune signaling after EYA2 transfection. (E) Representative micrographs (40×) of colony-forming capacity assays of control (i) or EYA2 inhibitor–treated (ii, 1 µM; iii, 10 µM) MDS bone marrow mononuclear cells showing significantly greater erythroid colonies in treated samples with accompanying quantitation for each of 3 independent samples (mean ± standard error). *P < .005, **P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal